Veterinary orodispersible tablets market seen reaching $1.65 billion by 2030

The veterinary orodispersible tablets market is projected to grow from $1.12 billion in 2025 to $1.65 billion by 2030, driven by rising pet healthcare spending, more pet ownership and demand for easier-to-administer medicines. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Veterinary orodispersible tablets are designed to make dosing pets easier, which can improve treatment adherence and reduce stress for animals and owners. - The category is expanding alongside broader growth in companion animal healthcare spending and demand for pet-friendly medication formats. - The market's projected rise to $1.65 billion by 2030 signals continued investment in more convenient veterinary drug delivery.

What happened: - The Business Research Company released a report on the veterinary orodispersible tablets market on July 13, 2026. - The market is estimated at $1.12 billion in 2025 and is forecast to reach $1.21 billion in 2026. - The market is projected to reach $1.65 billion by 2030, implying 8.1% compound annual growth from 2026 to 2030. - North America was the largest regional market in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - Veterinary orodispersible tablets are fast-dissolving oral medicines that disintegrate in the mouth without water. - The format is aimed at companion animals such as dogs and cats. - The report links growth to poor medication adherence in companion animals, difficulty giving traditional tablets, limited palatable veterinary medicines, reliance on conventional solid dosage forms and limited advanced drug-delivery technology in veterinary care. - The report cites rising preference for pet-friendly medication formats, wider adoption of precision drug delivery, higher spending on companion animal healthcare, pharmaceutical formulation advances and a stronger focus on treatment compliance. - Expected trend areas include taste-masked formulations, fast-disintegrating polymer matrices, precision-compounded low-dose tablets, advanced excipient engineering and stress-free medication delivery methods. - APPA reported total U.S. pet industry spending of $147 billion in 2023 and projected $152 billion in 2024. - APPA also said 94 million U.S. households owned at least one pet in 2025, up from 82 million in 2023. - The American Veterinary Medical Association said the number of veterinarians in the U.S. rose from about 124,069 in 2022 to about 127,131 in 2023. - The report's regional scope includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The company also said the 2026 report edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, plus updated graphics and tables. - The report offers a free sample and the full market report.

Between the lines: - The market growth story is less about a new therapeutic category and more about making existing veterinary treatment easier to give and easier to follow. - Rising pet ownership and higher spending on companion animals are reinforcing demand for dosage forms that fit routine care. - The infrastructure expansion in veterinary medicine suggests more channels for these products to reach pet owners.

What's next: - The market will likely track continued pet healthcare spending, product design improvements and adoption of more precise veterinary formulations. - Asia-Pacific's growth trajectory will be one of the key signals to watch as the category expands globally. - Product innovation around palatability, low-dose compounding and rapid disintegration could shape competitive positioning through 2030.